Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that a poster on Tonmya (cyclobenzaprine HCl sublingual tablets), investigated as TNX-102 SL, will be presented at the 2026 PainConnect Annual Meeting hosted by the American Academy of Pain Medicine (AAPM). The meeting is scheduled for March 5-8, 2026, in Salt Lake City, Utah, where the company will share data related to its investigational therapy as part of the scientific program.
Tonmya, the company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. The presentation at the AAPM meeting underscores the importance of this therapy for patients suffering from chronic pain conditions. Fibromyalgia affects millions of people worldwide, and the approval of Tonmya provides a new option for managing its debilitating symptoms.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind Tonmya in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The presentation at the AAPM PainConnect Annual Meeting is a critical step in disseminating clinical data to the medical community. Attendees will have the opportunity to review the poster and engage with researchers about the mechanisms and outcomes of Tonmya. This event highlights the ongoing commitment of Tonix to advancing treatments for chronic pain and CNS disorders.
For more information about the latest news and updates relating to TNXP, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/kwTPM.
